Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB122 in Advanced Solid Tumors
NCT04999761Phase 1Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of zimberelimab in solid tumor, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and 6 more (18 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at Day 28, Adverse Events at Day 28 and 2 more. Started Jun 2021; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT04999761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999761.